Ascendo Biotechnology receives the finalist recognition at the 2025 Moderna Taiwan mRNA Innovation Awards Ceremony.
Ascendo Biotechnology is honored to be selected as a finalist for the 2025 Moderna Taiwan mRNA Innovation Awards, recognizing the company’s continued leadership and innovation in immunology and next-generation biotechnology.
The awarded project represents an extension of Ascendo Biotechnology’s long-standing collaboration with Professor Yu-Hung Chen and his laboratory team at the College of Medicine at National Cheng Kung University (NCKU). Together, the teams previously co-developed ASD25x, a biodegradable nano-composite vaccine platform that has demonstrated the ability to robustly induce CD8⁺ T-cell responses and elicit a balanced Th1/Th2 immune profile in animal studies—highlighting its strong potential in vaccine and immunotherapy applications.
The selected project will further evaluate ASD25x as a novel delivery system for mRNA vaccines, aiming to establish a next-generation vaccine technology platform with Taiwan-based innovation and autonomy. This direction aligns closely with Ascendo’s core mission of advancing transformative therapies through cutting-edge science.
Ascendo Biotechnology will continue to collaborate with academic and clinical partners to accelerate pioneering technologies that shape the future of vaccines and immune-therapeutic development.
先知生物科技入圍「2025 莫德納台灣 mRNA 前瞻新創獎」決選
先知生物科技（Ascendo Biotechnology）榮獲 2025 莫德納台灣 mRNA 前瞻新創獎（Moderna Taiwan mRNA Innovation Awards）決選入圍，再度展現本公司在免疫醫學與創新生技領域的研發能量與前瞻布局。
本次入圍計畫由先知與國立成功大學醫學系陳毓宏教授及其實驗室團隊基於多年深度合作共同提出。雙方此前已開發 ASD25x——一項具備生物可降解特性的奈米複合疫苗平台，並在動物模型中證實其能有效誘導 CD8⁺ T 細胞反應，同時促進 平衡的 Th1/Th2 免疫應答。此技術成果奠定了 ASD25x 在疫苗與免疫治療應用上的重要基礎。
本計畫將進一步評估 ASD25x 作為新型 mRNA 疫苗遞送系統的潛力，期望為臺灣在次世代疫苗技術建立具有自主性的創新平台，同時亦與先知長期聚焦於創新療法的核心策略高度契合。
先知將持續與醫療與學術夥伴攜手推動前瞻生物技術，期待在未來的疫苗與免疫療法開發貢獻更具影響力的創新動能。
Celebrating Ascendo Biotechnology’s selection as a finalist in the 2025 Moderna Taiwan mRNA Innovation Awards.